Skip to content

Multimodal AI-assisted Surgical Decision and Prognosis Evaluation for Clear Cell Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus

Multimodal AI-assisted Surgical Decision and Prognosis Evaluation for Clear Cell Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600122178
Enrollment
Unknown
Registered
2026-04-09
Start date
2025-10-24
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clear Cell Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus

Interventions

Gold Standard:Assessment of IVC Wall Invasion: Histopathological confirmation of tumor invasion into the inferior vena cava wall Criteria for Rapid Thrombus Growth: The cranial extension of the tumor
Index test:Multimodal Evaluation System for Clear Cell Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus

Sponsors

The First Medical Center of the General Hospital of the People's Liberation Army of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age > 18 years. 2. Histologically confirmed clear cell renal cell carcinoma. 3. Voluntary participation with signed written informed consent.

Exclusion criteria

Exclusion criteria: 1. Presence of absolute contraindications to magnetic resonance imaging (MRI). 2. Severe artifacts on MRI images rendering them non-diagnostic. 3. Postoperative histopathological confirmation of any diagnosis other than clear cell renal cell carcinoma (ccRCC). 4. For retrospective cases: failure to complete multiparametric MRI (mpMRI) within 2 weeks prior to surgery, or received prior neoadjuvant therapy. 5. Received targeted therapy or immunotherapy at baseline, or presence of distant metastasis. 6. Concurrent with other malignancies.

Design outcomes

Primary

MeasureTime frame
Area under the receiver operating characteristic curve;

Secondary

MeasureTime frame
Sensitivity;Specificity;Accuracy;

Countries

China

Contacts

Public ContactHaiyi Wang

The First Medical Center of the General Hospital of the People's Liberation Army of China

wanghaiyi301@outlook.com+86 186 1203 2510

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026